Caring for Patients with End Stage Neurological Diseases

Caring for Patients with End Stage Neurological Diseases 

This course provides hospice and palliative care providers with detailed information about the pathophysiology, disease trajectory, and unique symptoms experienced by patients with advanced neurological diseases. Learners will identify the clinical features of advanced Parkinson's disease, amyotrophic lateral sclerosis, and Huntington disease as well as best practices for symptom management. In addition, hospice and palliative caregivers will learn the key clinical indicators and symptoms that should serve as triggers to optimally transition a patient with advanced neurological diseases to palliative and hospice care. The unique disease-related stressors for family caregivers are discussed and resources and suggestions are given for utilizing support from non-profit, disease-specific organizations.

$20.00

Hours: 1.50
REL-PAL-0-CPESND

Certificates

Certificates provided by accrediting body (11 Match)

California Board of Registered Nursing

1.5 HOURS


Provider approved by the California Board of Registered Nursing, CEP# 13791

Nurses will receive 1.50 contact hours for participating in this course.

District of Columbia Board of Nursing

1.5 HOURS


District of Columbia Board of Nursing Approved Continuing Education program (CEBroker Provider #50-290).


Nurses will receive 1.50 contact hours for participating in this course.

Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling

1.5 HOURS


Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling (CEBroker Provider #50-290).


This activity is approved for 1.50 contact hours.

Florida Board of Nursing

1.5 HOURS


Florida Board of Nursing (CEBroker Provider #50-290).


Nurses will receive 1.50 contact hours for participating in this course.

American Nurses Credentialing Center

1.5 HOURS


In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Association of Social Work Boards

1.5 HOURS


Relias, LLC, #1273, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Relias LLC maintains responsibility for this course. ACE provider approval period: 02/10/2018-02/10/2021.


Course Delivery Format: Asynchronous Distance Learning-interaction includes quizzes with questions and answers, post-tests.


This module is Recorded Webinar.


Social workers completing this course receive 1.50 Clinical continuing education clock hours.

New York State Education Department, Office of the Professions, Division of Professional Licensing Services, Social Work Unit

1.5 HOURS


Relias, LLC is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0009.

Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of licensed master social work and licensed clinical social work in New York. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice for an LMSW and LCSW. A licensee who practices beyond the authorized scope of practice could be charged with unprofessional conduct under the Education Law and Regents Rules.

As a provider of online, asynchronous education, some courses offered by Relias Learning are considered “self-study” under section 74.10(c)(2)(ii)(b)(4) of the Commissioner’s Regulations. The regulations limit self-study activities taken from a provider approved by the Education Department to no more than 12 hours in the 36-month registration period or one-third of the hours in a registration period other than 36 months.

Social workers will receive 1.50 continuing education hours for participating in this course. This activity is approved for 1.50 contact hours.

Georgia Board of Nursing

1.5 HOURS


Georgia Board of Nursing (CEBroker Provider #50-290).


Nurses will receive 1.50 contact hours for participating in this course.

South Carolina Board of Nursing

1.5 HOURS


This program was approved by the South Carolina Board of Nursing Approved Continuing Education Program (CEBroker Provider #50-290).


Nurses will receive 1.50 contact hours for participating in this course.

West Virginia Board of Registered Nursing

1.5 HOURS


West Virginia Board of Registered Nursing (CEBroker Provider #50-290).


Nurses will receive 1.50 contact hours for participating in this course.

Ohio Social Worker Board

1.5 HOURS


Ohio Counselor, Social Worker and Marriage and Family Therapist Board
Provider #
CEBroker Provider: 50-290
This activity is approved for 1.50 contact hours.

Course Details

Course Code: REL-PAL-0-CPESND
Hours: 1.5
Type: Online Course
Content Expiration Date: 9/30/2020
Learning Objectives:
Outline assessment for neurological symptom management.
Identify specific patterns of progression for neurological disorders.
Identify complications commonly related to neurological disorders.
Describe common treatment and symptom management options related to neurological disorders.

Outline:
Section 1: Introduction A. Learning Objectives Section 2: Parkinson’s Disease A. Who Gets Parkinson’s Disease (PD)? B. Epidemiology of PD C. Parkinsonism D. Classification of Parkinson Syndromes in a Community E. Non-Motor Symptoms of PD F. Associated Problems – Late G. Red Flags Parkinsonism May Not Be Parkinson Disease H. Some Causes of Parkinsonism I. Drug-Induced Parkinsonism J. Vascular Parkinsonism K. Progressive Supranuclear Palsy L. Multiple Systems Atrophy (MSA) M. Cortical Basilar Ganglionic Degeneration (CBGD) N. Dementia with Lewy Bodies (DLB) O. Evolving PD Diagnostic Criteria include Dementa P. Clinical Staging: Modified Hoehn and Yahr Q. Mortality in Parkinsonism R. Treatments S. Medication Options Section 3: Amyotrophic Lateral Sclerosis (ALS) A. What is ALS? B. ALS C. What Causes ALS? D. Diagnosis and Progression of ALS E. Other Risks in ALS F. Treatment Goals When There Is No Cure Section 4: Huntington’s Disease A. Epidemiology B. Genetic Disease C. Trio of Disorders: 3 Ms D. Movement Disorder E. Speech/Communication F. Swallowing G. Cognitive & Behavioral Disorder H. Psychiatric Manifestations I. Advanced Disease J. Causes of Death K. Treatments – Symptomatic L. Treatments – Non-pharmacologic M. Issues in Advanced Disease N. Rate of Progression O. Average Characteristics of Patients in Extended Care P. Medical Issues in Advanced HD Q. Everyday Issues in Advanced HD R. Small Interventions Can Make Large Differences S. Medications Can Be Used in Advanced HD T. HD is a Family Disease Section 5: Conclusion A. Resources B. References

Expert Reviewer: Samuel Frank, MD
Dr. Samuel Frank is Associate Professor of Neurology and co-Director of Neurology Resident Education at Boston University. Since completing his fellowship in Experimental Therapeutics (Movement Disorders) at the University of Rochester, he has established active general movement disorders, Huntington's Disease, and dystonia clinics at Boston University and the New England Regional VA Hospital. He also serves as the inpatient neurology consultant for the Huntington’s Disease service at Tewksbury State Hospital, a state-run chronic care hospital. Regarding research, Dr. Frank has served as the site investigator for multiple clinical trials including those coordinated through the Huntington Study Group, Parkinson Study Group, Michael J. Fox Foundation, National Science Foundation, NIH and other independent studies. He played a key role as medical monitor for the clinical trials in the US of tetrabenazine for chorea associated with Huntington’s disease. He has published in the areas of Huntington’s disease, education and research ethics, determining why patients chose (or refuse to) participate in invasive research studies for Parkinson’s disease. He has also served on data safety monitoring committees. Dr. Frank has played a strong role in advocacy for patients, serving as the consumer representative for the Peripheral and Central Nervous System Advisory Committee for the FDA. He is an active member as a member of the board of trustees for the Huntington Disease Society of America (HDSA) and has chaired the National HDSA Education Subcommittee. Dr. Frank is also currently serving as a member of the Patient Safety Subcommittee at the American Academy of Neurology. Disclosure: Samuel Frank, MD discloses the following potential conflict of interests/commercial interests: Relevant Financial Relationship with Teva as Grant/Research Support
Target Audience:
The target audience for this course is: Beginner level Social Workers; Nurses; in the following settings: Hospice, Palliative Care.
Relias will be transparent in disclosing if any commercial support, sponsorship or co-providership is present prior to the learner completing the course.
Course Delivery Method and Format
Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.
Accommodations
If you require special accommodations to complete this module, please contact Relias Customer Support here.